Trial report in BMJ (Clinical research ed.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04485195 (RAFF4 Trial), which is not on this map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
27 authors.
Ian G StiellDepartment of Emergency Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.ORCID 0000-0002-2583-6408
Monica TaljaardOttawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.ORCID 0000-0002-3978-8961
Debra EaglesDepartment of Emergency Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.ORCID 0000-0002-7454-2721
Krishan YadavDepartment of Emergency Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.ORCID 0000-0002-1547-4634
Alain VadeboncoeurInstitut de Cardiologie de Montréal, Université de Montréal, Montréal, Québec, Canada.ORCID 0000-0002-9341-0695
Corinne M HohlDepartment of Emergency Medicine, Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0002-9210-7838
Patrick M ArchambaultDépartement de médecine familiale et de médicine d'urgence et Département d'anesthésiologie et de soins intensifs, Centre de recherche du Centre intégré de santé et de services sociaux de Chaudière-Appalaches, Université Laval, Québec City, Québec, Canada.ORCID 0000-0002-5090-6439
David BirnieDivision of Cardiology, University of Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada.ORCID 0000-0001-6495-1428
Erica BrownOttawa Hospital Research Institute, Ottawa, Ontario, Canada.
Samuel G CampbellDepartment of Emergency Medicine, Dalhousie University, Halifax, Canada.
Yutong ChenOttawa Hospital Research Institute, Ottawa, Ontario, Canada.
Catherine M ClementOttawa Hospital Research Institute, Ottawa, Ontario, Canada.
Alexis CournoyerCentre intégré universitaire de santé et de services sociaux (CIUSSS) du Nord-de-l'Île de-Montréal, Sacré-Coeur Hospital, Département de médecine de famille et médecine d'urgence, Montréal, Québec, Canada.ORCID 0000-0003-2565-0029
Kerstin de WitDepartment of Emergency Medicine, Queen's University, Kingston, Ontario, Canada.ORCID 0000-0003-2763-6474
Marcel EmondCHU de Québec, Hôpital de l'Enfant-Jésus, Division of Emergency Medicine, Université Laval, Québec City, Québec, Canada.ORCID 0000-0001-7158-8110
Laurent MacleInstitut de Cardiologie de Montréal, Université de Montréal, Montréal, Québec, Canada.ORCID 0000-0002-3328-5239
Andrew D McRaeDepartment of Emergency Medicine, and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.ORCID 0000-0003-2743-4290
Eric MercierDepartment of Family Medicine and Emergency Medicine, Centre de Recherche du CHU de Québec, Université Laval, Québec City, Québec, Canada.
Judy MorrisDepartment of Family Medicine and Emergency Medicine, Université de Montréal, Montréal, Québec, Canada.ORCID 0000-0002-6972-3771
Ghadeer MohamadOttawa Hospital Research Institute, Ottawa, Ontario, Canada.
Marie-Joe NemnomOttawa Hospital Research Institute, Ottawa, Ontario, Canada.ORCID 0000-0002-0102-1984
Stuart G NichollsMethodological & Implementation Research (MIR), Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.ORCID 0000-0003-0485-9069
David PareInstitut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec City, Québec, Canada.ORCID 0000-0003-0177-6428
Ratika ParkashDivision of Cardiology, Department of Medicine, Dalhousie University, Dartmouth, Nova Scotia, Canada.ORCID 0000-0001-7630-7795
Marco LA SivilottiDepartment of Emergency Medicine, Queen's University, Kingston, Ontario, Canada.ORCID 0000-0001-6641-1118
Kednapa ThavornOttawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.ORCID 0000-0003-4738-8447
Jeffrey J PerryDepartment of Emergency Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.ORCID 0000-0003-2134-9597
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
objectiveTo conduct a randomised, open label comparison of the effectiveness and safety of intravenous vernakalant and intravenous procainamide for the management of acute atrial fibrillation in the emergency department.
designRandomised clinical trial (RAFF4 trial).
setting12 tertiary care emergency departments in Canada.
participantsPatients with acute atrial fibrillation for whom acute rhythm control was a safe option.
interventionsPatients were randomised (1:1) to an intravenous infusion of vernakalant or procainamide; when rapid conversion did not occur, patients were offered electrical cardioversion. MAIN OUTCOMES AND MEASURES: The primary outcome was conversion to sinus rhythm within 30 minutes of drug infusion completion. Secondary outcomes included time to conversion to sinus rhythm and whether the patient required electrical cardioversion.
resultsOf the 350 enrolled eligible patients, baseline characteristics were similar in the procainamide (n=172) and vernakalant (n=178) groups. For the primary outcome of conversion success, vernakalant was more effective (62.4%
conclusionsIn this head-to-head comparison, vernakalant was superior to procainamide for patients with higher conversion rates and faster times to conversion. Therefore, vernakalant is a safe and highly effective intravenous alternative for the rapid cardioversion and discharge home of patients with acute atrial fibrillation.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Vernakalant versus procainamide for rapid cardioversion of patients with acute atrial fibrillation (RAFF4): randomised clinical trial. · full record | OpenQuestion